Erdafitinib Liver Cancer

Currently, Erdafitinib (Erdafitinib) is not mainly used to treat liver cancer. Erdafitinib is a pan-FGFR inhibitor recently approved in the United States for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. FGFR is a protein associated with cell growth and differentiation that can be mutated in specific tumor types. However, this mutation is uncommon in liver cancer. If a patient is diagnosed with liver cancer, it is recommended to consult a professional doctor for the most accurate and individually tailored treatment recommendations.

ErdafitinibThe drug is also being studied to treat other cancers, including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma and esophageal cancer. For patients with liver cancer, currently recommended first-line treatments usually include surgical resection, ablation therapy, radiotherapy, and transarterial chemoembolization. In addition, molecular targeted drugs such as sorafenib and rapatinib are also widely used in the treatment of liver cancer. These drugs interfere with the growth and spread of tumor cells, thereby extending patient survival.

The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).